Stryker (SYK) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $3.69
- Estimate
- $3.49
- Surprise
- +5.8%
- Score at report (before → after)
- 5.6 → 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Stryker (SYK) beat the $3.49 estimate with adjusted EPS of $3.69 — a clear 5.8% upside surprise. TrendMatrix's engine moved from Hold (5.6/10) to Sell at 5.4/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates SYK Buy (Wait) at 5.8/10.
3 of the last 4 quarters beat the estimate; this quarter's +5.8% surprise compares with a -0.9% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.5 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: MedSurg and Neurotechnology (62.0%)
- Concentration risk — Supplier: sole-source suppliers
- Thin upside margin: 5.9%
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $308.04
- Entry target
- $299.96
- Price target
- $326.35
- Stop
- $283.22
- Upside to target
- +5.9%
- Reward-to-risk
- 0.5:1
The stock trades at 31.5× trailing but 18.3× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 77 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
SYK at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $116.61B
- P/E (fwd)
- 18.3
- P/E (ttm)
- 31.5
- 52-week range
- $267.00–$389.33
- Off 52-week high
- 20.9%
- RSI (14)
- 77
- Volume vs avg
- 0.13×
- Score today
- 5.8/10